Previous studies indicate that deficiency of endothelial nitric oxide synthase (eNOS)-derived NO exacerbates myocardial reperfusion injury. We hypothesized that overexpression of eNOS would reduce the extent of myocardial ischemia-reperfusion (MI-R) injury. We investigated two distinct strains of transgenic mice overexpressing the eNOS gene (eNOS Tg). Bovine eNOS was overexpressed in one strain (eNOS TgKobe) while the human eNOS gene was overexpressed in the other strain (eNOS Tg-RT). Nontransgenic and eNOS Tg mice were subjected to 30 minutes of coronary artery occlusion followed by 24 hours of reperfusion and the extent of myocardial infarction was determined. Myocardial infarct size was reduced by 33% in the eNOS Tg-Kobe strain (p < 0.05 vs. NTg) and by 32% in the eNOS Tg-RT strain (p < 0.05 vs. NTg). However, post-ischemic cardiac function (cardiac output, fractional shortening) was not improved in the eNOS Tg-Kobe mouse at 24 hours of reperfusion (p = NS vs. NTg). In additional studies, eNOS Tg-Kobe were subjected to 30 min. of MI and 7 days of reperfusion. Fractional shortening and left ventricular dP/dT were measured in eNOS Tg-Kobe and NTg mice and no significant differences in contractility were observed (p = NS) between the eNOS Tg and the NTg controls. Left ventricular end-diastolic pressure was significantly (p < 0.05 vs. NTg) reduced in the eNOS Tg-Kobe strain at 7 days of reperfusion. The cardioprotective effects of eNOS overexpression on myocardial infarct size were ablated by L-NAME (300mg/Kg) pretreatment. Thus, genetic overexpression of eNOS in mice attenuates myocardial infarction following MI-R, but fails to significantly protect against post-ischemic myocardial contractile dysfunction in mice.
Introduction
Nitric oxide is constitutively produced by the vascular endothelium by endothelial nitric oxide synthase (eNOS) and serves to protect against cardiovascular disease.
Nitric oxide promotes vasodilation (4, 7) , regulates leukocyte-endothelial cell interactions (17) , inhibits platelet adhesion and aggregation (9, 22) , attenuates smooth muscle cell proliferation (8) , and may modulate cardiac myocyte function (16) . Since the discovery of endothelium-derived relaxing factor (EDRF) in 1980, NO has been implicated in numerous disease states as both a beneficial and a deleterious moiety. Attenuated eNOS function and reduced NO generation is a critical early event in many cardiovascular diseases (9) . NO therapy utilizing physiological levels of NO is beneficial in a number of pathophysiological states including hypercholesterolemia (9) , diabetes mellitus (9) , and ischemia-reperfusion injury (11, 17, 18) .
A number of previous studies have demonstrated that treatment with various NOdonating compounds is highly effective in the setting of myocardial ischemia-reperfusion (MI-R) injury (3, 20, (28) (29) (30) . NO has also recently emerged as a crucial modulator of myocardial preconditioning and both eNOS-derived and iNOS-derived NO are thought to mediate cardioprotection during the preconditioning process (33, 36) . Furthermore, MI-R injury is significantly enhanced in eNOS-deficient animals when compared to wildtype controls (12) . Pharmacological inhibition of NO synthesis exacerbates MI-R injury (28) while administration of the NO-precursor, L-arginine can ameliorate MI-R injury (23, 29, 32) .
Recently, transgenic mice that overexpress the eNOS gene have been developed (25, 31) . Previous studies of eNOS overexpression have focused primarily on shock states (34) and atherosclerosis (26, 31) . While, genetic overexpression of eNOS has been shown to protect against endotoxin shock (34) , the effects of eNOS overexpression in the setting of hypercholesterolemia and atherogenesis are somewhat controversial at present with conflicting reports in the literature (26, 31) .
In the present study, we endeavored to determine whether overexpression of endothelial NOS could affect the severity of MI-R injury in an in vivo murine model of acute myocardial ischemia and reperfusion injury. Specifically, we sought to examine two distinct strains of eNOS transgenic mice and to evaluate the effects of eNOS overexpression on myocardial infarct size and post-ischemic myocardial contractile function. Two distinct strains of eNOS transgenic (eNOS Tg) mice were utilized in the present studies. One eNOS transgenic mouse was developed in Kobe, Japan (eNOS Tg-Kobe) and featured the murine prepoendothelin-1 promoter (GenBank accession number U07982) and bovine eNOS cDNA (GenBank accession number M99057). This mouse was developed on a C57BL/6 background and has been extensively characterized previously (15,25-27, 34,35 ).
Methods eNOS Transgenic Mice:
An additional eNOS Tg mouse was recently developed in Rotterdam (31), the Netherlands (eNOS Tg-RT) and these mice were also used in the present study of myocardial ischemia-reperfusion injury. A DNA fragment containing the human eNOS gene was isolated from a homemade human genomic cosmid library (10) using eNOS cDNA (kindly donated by Dr. S. Janssens, Leuven, Belgium as a probe (31) . In addition, the DNA fragment contained ~6kb of 5' natural flanking sequence, including the native eNOS promoter, and ~3kb of 3' sequence to the gene. Thus, promoter DNA elements were included that have been shown to be essential in transcriptional regulation as well as elements responsible for the tissue distribution of eNOS expression (19) . Also, the endothelium enhancer element that is located 4.9 kilobases upstream from the transcription start site of the eNOS gene is included in this construct.
Vector sequences were removed by restriction endonucleases. A solution of 1-2 µg/mL of DNA was used for microinjection of fertilized oocytes from FVB donor mice and transplanted into the oviducts of pseudopregnant B10xCBA mice. Founder mice and offspring were genotyped by PCR on DNA isolated from tail biopsies. Primers used were5'-GTCCTGCAGACCGTGCAGC-3'(sense)and 5'-GGCTGTTGGTGTCTGAGCCG-3' (antisense). Mice were backcrossed to C57BL/6 for at least seven generations (~99% C57BL/6). The individual performing all experiments was blinded to the ouse genotype until all data were fully analyzed. All experiments performed at LSU Health Sciences Center conformed to state and federal regulations regarding animal experimentation and with the American Physiological Society Guidelines.
Myocardial Infarction Protocol:
Ligation of the left main coronary artery was performed similar to methods described previously (12, 13) . Briefly, mice were anesthetized with intraperitoneal injections of ketamine (50 mg/kg) and pentobarbital sodium (50 mg/kg). The animals were then attached to a surgical board with their ventral side up. The mice were orally intubated with PE-90 polyethylene tubing connected to PE-240 tubing and then connected to a Model 683 rodent ventilator (Harvard Apparatus, Natick, MA) The tidal volume was set at 2.2 milliliters and the respiratory rate was set at 122 breaths per minute. The mice were supplemented with 100% oxygen via the ventilator side port. A median sternotomy was performed using an electric cautery and the proximal left main coronary artery was visualized and completely ligated with 7-0 silk suture mounted on a tapered needle (BV-1, Ethicon).
In additional experiments both nontransgenic and eNOS transgenic mice (eNOS Tg-Kobe) were subjected to coronary artery ligation for 30 minutes and 24 hours of reperfusion. All of the mice were treated with 5-hydroxydecanoic acid (5-HD) at a dose of 10 mg/kg 30 minutes prior to left main coronary artery ligation (24) . An additional group of eNOS Tg-Kobe Mice (n=7) were treated with 300 mg/Kg of L-NAME (i.p. injection) 30 minutes prior to left main coronary artery ligation. The mice receiving L-NAME were subjected to 30 minutes of left main coronary artery ligation and 24 hours of reperfusion. Additional studies were also performed in C57BL/6 mice (n=6 per group) treated with the NO donor, DPTA NONOate (Alexis Pharmaceuticals, San Diego, CA).
In these experiments mice were subjected 30 minutes of myocardial ischemia and 24 hours of reperfusion. DPTA NONOate (100 µg/Kg) was administered 5 minutes prior to coronary artery reperfusion via direct injection into the left ventricular cavity.
Myocardial Infarct Size Determination: At 24 hours of reperfusion, the mice were anesthetized as described previously, intubated, and connected to a rodent ventilator. A catheter (PE-10 tubing) was placed in the common carotid artery to allow for Evans Blue dye injection. A median sternotomy was performed and the left main coronary artery was re-ligated in the same location as before. Evans Blue dye (1.2 mL of a 2% solution) was injected into the carotid artery catheter into the heart to delineate the ischemic zone from the nonischemic zone. The heart was rapidly excised and serially sectioned along the long axis in 1 mm thick sections that were then incubated in 1.0% 2,3,5-triphenyltetrazolium chloride for 5 minutes at 37°C to demarcate the viable and nonviable myocardium within the risk zone. Each of the five, 1 mm thick myocardial slices were weighed and the areas of infarction, risk, and nonischemic left ventricle were assessed by a blinded observer using computer-assisted planimetry (NIH Image 1.57). All of the procedures for area-at-risk and infarct size determination have been previously described (12, 13) .
Evaluation of Arterial and Left Ventricular Hemodynamics: At 7 days
following myocardial ischemia and reperfusion, a 1.4 Fr Millar (SPR-671; Houston, TX) pressure transduction catheter was inserted similar to methods described previously (21) . Data for each animal was calculated from at least 10 seconds of chart recording (arithmetic mean of at least 50 cardiac cycles). interfaced with a Sequoia C256 (Acuson) was performed in groups of mice following either 24 hours or 7 days of reperfusion following 30 minutes of LAD ligation. Twodimensional echocardiography was performed as described previously (13, 14) . All data were calculated from 10 cardiac cycles per experiment. 
Echocardiographic Assessment of Left

Results eNOS Transgenic Mice-Kobe Hemodynamics
Mean arterial blood pressure ( Figure 1 ) was measured in the eNOS Tg-Kobe and nontransgenic (NTg) control animals. Blood pressure was 84 ± 4 mmHg in the nontransgenic group and 77 ± 7 mmHg in the eNOS Tg group (p = NS). Similarly, baseline heart rates ( Table 1) were similar in the nontransgenic (340 ± 18) and eNOS Tg (333 ± 10) groups.
Myocardial Infarct Size
Myocardial area-at-risk (AAR) per left ventricle (LV) and infarct size per AAR data following 30 minutes of LAD occlusion and 24 hours of reperfusion are presented for nontransgenic (NTg) controls (n=11) and eNOS transgenic (Tg) mice (n=10) in Figure 2 .
The areas-at-risk per LV were similar (p = NS) in the NTg and eNOS Tg-Kobe mice (46 ± 3% and 52 ± 3%, respectively). Myocardial infarct size per area-at-risk was 43 ± 3% in the NTg group and 29 ± 4 in the eNOS Tg group (p > 0.05 between the groups). In eNOS Tg mice treated with L-NAME (n=7) prior to myocardial ischemia the area-at-risk per LV was 58 ± 4% (p = NS compared to NTg and eNOS Tg alone) and myocardial infarct size per area-at-risk was 37 ± 4% (p = NS compared to NTg group and p < 0.05 compared to eNOS Tg group). In additional experiments we investigated the effects of L-NAME treatment of eNOS Tg mice at dosages of 50 mg/Kg and 100 mg/Kg and failed to observe any changes in myocardial infarct size compared to vehicle (data not shown).
Baseline and Post-Ischemic Cardiac Function (30 min. MI and 24 hours of Rep.)
Baseline and Post-ischemic cardiac function data are presented in Tables 1 and   2 . No group differences in heart rate (HR), stroke volume (SV), cardiac output (CO), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), or fractional shortening were observed at baseline. Following myocardial ischemia and reperfusion heart rate was significantly (p < 0.05) reduced both the NTg 
Myocardial Infarct Size in Wild-Type Mice with NO Donor Therapy
The effects of NO donor therapy (DPTA NONOate) were evaluated in nontransgenic, wild-type mice (n=6 per group) and these data are presented in Figure 9 .
The area-at-risk per left ventricle was 61 ± 4% in untreated wild-type mice and 63 ± 4% in wild-type mice treated with DPTA (p = NS between groups). Infarct size per area-atrisk was 45 ± 3% in wild-type controls and 21 ± 2% in mice treated with DPTA (p < 0.01 between groups).
Discussion
Data from the present study provide evidence for a beneficial role of genetic overexpression of eNOS in the setting myocardial ischemia-reperfusion injury.
Myocardial infarct size was reduced by approximately 33% in two distinct strains of eNOS transgenic mice. The bovine eNOS gene was overexpressed in one mouse strain while the human eNOS gene was overexpressed in the other mouse strain. eNOS genetic expression varied from about 6-12 fold in these transgenic mice and eNOS protein expression was confined primarily to the vascular endothelium (14, 25, 26, 31) . All of these improvements occurred in the eNOS Tg mice without changes in systemic hemodynamics or differences in baseline ventricular morphology and function. Despite the significant reduction in myocardial infarct size; we failed to observe any significant preservation of post-ischemic myocardial contractile function as assessed by echocardiography or by left ventricular direct catheterization studies when evaluated at 24 hours or 7 days following myocardial infarction. It is likely that the reduction in myocardial infarct size, although significant, was not of a great enough magnitude to induce protection against post-ischemic contractile dysfunction.
Treatment of eNOS transgenic mice with the nitric oxide synthase inhibitor L-NAME attenuated the cardioprotection observed with eNOS overexpression. These data support a cardioprotective role for eNOS in MI-R injury and further support previous studies of eNOS deficient mice and studies of NO donors in acute MI-R injury.
Previous experimental studies of eNOS transgenic mice have revealed a very interesting phenotype that results from genetic overexpression of eNOS. eNOS transgenic mice have been shown to be protected against endotoxin shock (34) and display systemic hypotension (25, 31) . The eNOS Tg mice display reduced NOmediated vasodilator responses and appear to exhibit a nitrate tolerance (25, 35) .
Additionally, eNOS overexpression has been shown to limit neointimal lesion formation and medial thickening in a model of vascular remodeling (15) . Overexpression of eNOS has also been shown to protect against skeletal muscle ischemia-reperfusion injury (27) . Reductions in skeletal muscle I/R injury were accompanied by a reduction in leukocyte-endothelial cell adhesion molecules and leukocyte trafficking into the ischemic tissue (27) . Our laboratory has recently demonstrated (14) that genetic overexpression of eNOS significantly attenuates the severity of congestive heart failure following severe myocardial infarction in mice. Our previous study (14) clearly demonstrated significant improvements in survival and cardiac function at 30 days following myocardial infarction in the Rotterdam eNOS transgenic mouse compared to nontransgenic controls. The role of eNOS-derived NO in atherogenesis has been extensively investigated. Two strains of eNOS-Tg mice have been bred onto the ApoEdeficient mice as a means to study the potential role of NO in atherosclerosis.
Interestingly, conflicting reports have emerged with one group reporting that eNOS overexpression accelerates atherosclerotic lesion formation (26) and the other group reporting attenuated atherosclerotic lesion formation (31) . Finally, both eNOS and iNOS have been selectively overexpressed within cardiac myocytes (1, 6) . Cardiac myocyte-specific eNOS overexpression has been shown to blunt cardiac myofilament Ca 2+ sensitivity without any alterations in systemic hemodynamics (1) whereas cardiacspecific iNOS overexpression did not alter cardiac function (6).
Our laboratory and others have previously reported that NO-donating agents significantly reduce the extent of myocardial reperfusion injury in various animal model systems (3, 20, 23, (28) (29) (30) . In addition, our laboratory and others have previously demonstrated that exogenous NO-therapy does protect against post-ischemic myocardial contractile dysfunction (3, 28, 29) and that inhibition of NO promotes postischemic myocardial contractile dysfunction (5, 29) . Furthermore, genetic deficiency of the eNOS enzyme significantly exacerbates myocardial I/R injury (12) . The present study provides additional support for the cardioprotective actions of NO in the setting of myocardial reperfusion injury. However, the extent of myocardial infarct size reduction observed in the present study (i.e., 32-33%) was significantly less than that reported in previous studies of exogenous NO-donors (i.e., > 50-65% reductions in infarct size).
Furthermore, we administered the NO donor DPTA NONOate to wild-type mice in the present study and observed a highly significant 53% reduction in myocardial infarct size.
One possible explanation for this apparent discrepancy is that the eNOS Tg mice are exposed to elevated NO levels for the time of birth (i.e., chronic exposure) whereas NOdonors have been administered to wild-type animals only for a short period of time. and eNOS transgenic (eNOS Tg-RT) at baseline, during ischemia, and reperfusion.
Blood pressure was measured in anesthetized mice. Blood pressure was measured at 25 minutes of ischemia and also at 2 hours following reperfusion. "n" numbers are located inside the bars. 
